Upstream Bio, Inc. — Form 8-K
Filed September 1, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Following FDA End-of-Phase 2 meetings, Upstream Bio announced pivotal Phase 3 development plans for verekitug: two placebo-controlled trials (one per indication) enrolling ~1,500 patients total, dosing 400mg subcutaneously every 12 weeks, with initiation planned Q1 2027. Primary endpoints are annualized asthma exacerbation rates (48 weeks) for asthma and nasal polyp/congestion scores (48 weeks) for CRSwNP. Company expects potential BLA submission and launch as early as 2030 pending positive results.
Why this rating
Clinical-stage biotech with ~$468M market cap advancing sole lead candidate through FDA-aligned Phase 3 gates in two large indications represents meaningful de-risking and potential near-term catalyst. Event is significant relative to company size but not business-transforming until data emerges.
Price action (we called it positive)
before filing · preread $6.70 ▲ 1.21% | at our read · unknown $6.62 | +10 min · unknown $6.62 ▲ 0.00% | +30 min · unknown $6.62 ▲ 0.00% | +1 hr pending | +4 hrs pending |
The stock had already moved -1.19% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.